Asterias Announces Two Significant Developments for Spinal Cord Injury Program

Home/News/News/Asterias Announces Two Significant Developments for Spinal Cord Injury Program

Asterias Announces Two Significant Developments for Spinal Cord Injury Program

67% of Cohort 2 subjects have recovered two or more motor levels on at least one side through 12 months

AST-OPC1 receives Regenerative Medicine Advanced Therapy (RMAT) designation from FDA

FREMONT, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) — Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company pioneering the field of regenerative medicine, today announced new 12-month data from the first efficacy cohort in the company’s ongoing Phase 1/2a SCiStar study designated to evaluate safety and efficacy of AST-OPC1.   The 12-month data showed 67% (4/6) of Cohort 2 (AIS-A injuries administered 10 million AST-OPC1 cells) subjects have recovered 2 or more motor levels on at least one side through 12 months, which is more than double the rates of recovery seen in both matched historical controls and published data in a similar population.  Also, the FDA granted the company’s request for AST-OPC1 to be designated a Regenerative Medicine Advanced Therapy (RMAT) under the 21st Century Cures Act.


Original source of this content: https://globenewswire.com/news-release/2017/10/02/1138619/0/en/Asterias-Announces-Two-Significant-Developments-for-Spinal-Cord-Injury-Program.html